Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting... see more

Recent & Breaking News (CSE:DTC)

Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins

Newsfile April 10, 2023

Defence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX(TM) Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute

Newsfile March 28, 2023

Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million

Newsfile March 17, 2023

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile March 16, 2023

Defence Therapeutics (CSE:DTC) to develop new cancer treatment with nuclear energy group

Caroline Egan  March 14, 2023

Defence Therapeutics Signs Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer

Newsfile March 14, 2023

Defence's Pipeline Advances to Multiple Phase I Clinical Trials

Newsfile February 27, 2023

Defence Delegates City of Hope to Initiate IND Filing for Its AccuTOX(TM) Cancer Program

Newsfile February 21, 2023

RETRANSMISSION: Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors

Newsfile February 6, 2023

Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors

Newsfile February 3, 2023

Defence Therapeutics (CSE:DTC) and CQDM to fund new cancer vaccine platform

Brieanna McCutcheon  February 2, 2023

Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform

Newsfile February 2, 2023

Defence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances

Newsfile January 31, 2023

Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated

Newsfile January 24, 2023

RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023

Newsfile January 23, 2023

Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023

Newsfile January 20, 2023

Defence Therapeutics (CSE:DTC) issued notice of allowance for its proprietary Accum technology

John Ballem  January 16, 2023

Defence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP

Newsfile January 16, 2023

mRNA with Defence's Accum(TM) Program Has Been Initiated

Newsfile January 10, 2023

Defence Therapeutics' (CSE:DTC) AccuTOX reduces cancer nodules

Caroline Egan  December 20, 2022

Podcasts